Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Feb;42(2):e15427.
doi: 10.1111/dme.15427. Epub 2024 Aug 27.

Complement anaphylatoxins: Potential therapeutic target for diabetic kidney disease

Affiliations
Review

Complement anaphylatoxins: Potential therapeutic target for diabetic kidney disease

Jingyuan Ma et al. Diabet Med. 2025 Feb.

Abstract

Diabetic kidney disease (DKD) is the most common cause of kidney failure, characterized by chronic inflammation and fibrosis. The complement system is increasingly implicated in the development and progression of diabetic nephropathy. The important complement anaphylatoxins C3a and C5a are key mediators of the innate immune system, which regulates cellular inflammation, oxidative stress, mitochondrial homeostasis and tissue fibrosis. This review summarizes the involvement of anaphylatoxins in the pathogenesis of diabetic kidney disease, highlights their important roles in the pathophysiologic changes of glomerulopathy, tubulointerstitial damage and immune cell infiltration, and discusses the modulatory effects of new anti-diabetic drugs acting on the complement system. Based on available clinical data and findings from the preclinical studies of complement blockade, anaphylatoxin-targeted therapeutics may become a promising approach for patients with DKD in the future.

Keywords: anaphylatoxins; complement; diabetic kidney disease.

PubMed Disclaimer

Conflict of interest statement

The authors have no conflict of interest to declare.

Figures

FIGURE 1
FIGURE 1
The complement cascade and anaphylatoxin formation. The complement cascade consists of a series of enzymatic reactions that respond to infection and danger signal in the immune system. The complement cascade is activated through three different pathways, namely classical, lectin and alternative pathways. These pathways converge at the cleavage of C3 to produce C3a (anaphylatoxin) and C3b. Excess C3b binds with C4b2a (C3 convertase) to form C4b2aC3b (C5 convertase), which cleavages C5 into C5a (anaphylatoxin) and C5b. Finally, C5b mediates the formation of membrane attack complex (MAC) that forms pores on the cellular membrane, resulting in cell death. This figure was created using BioRender.
FIGURE 2
FIGURE 2
The role of anaphylatoxins in DKD. Hyperglycaemia activates the complement system in patients with diabetes that generates anaphylatoxins C3a and C5a, which bind to the corresponding receptors (C3aR, C5aR1 and C5aR2) on various kidney resident cells (podocytes, glomerular endothelial cells and tubular epithelial cells) and recruited immune cells that orchestrate cellular responses to diabetes‐induced damage including inflammation, oxidative stress, mitochondrial dysfunction, epithelial–mesenchymal transition (EMT) and endothelial–myofibroblast transition (EndMT). Prolonged kidney injury and maladaptive repair result in DKD with kidney fibrosis and progressive loss of kidney function. This figure was created using BioRender.

Similar articles

References

    1. Sun H, Saeedi P, Karuranga S, et al. IDF diabetes atlas: global, regional and country‐level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res Clin Pract. 2022;183:109119. - PMC - PubMed
    1. de Boer IH, Khunti K, Sadusky T, et al. Diabetes management in chronic kidney disease: a consensus report by the American Diabetes Association (ADA) and kidney disease: Improving Global Outcomes (KDIGO). Diabetes Care. 2022;45(12):3075‐3090. - PMC - PubMed
    1. Tong L, Adler SG. Diabetic kidney disease. Clin J Am Soc Nephrol. 2018;13(2):335‐338. - PMC - PubMed
    1. Hu Q, Chen Y, Deng X, et al. Diabetic nephropathy: focusing on pathological signals, clinical treatment, and dietary regulation. Biomed Pharmacother. 2023;159:114252. - PubMed
    1. Tuttle KR, Agarwal R, Alpers CE, et al. Molecular mechanisms and therapeutic targets for diabetic kidney disease. Kidney Int. 2022;102(2):248‐260. - PubMed

MeSH terms